Cytokine-Based Immunotherapy - Part A

Erscheinungsjahr 2025
ISBN: 978-0-443-29726-7
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Cytokine-Based immunotherapy, Volume 396, Part A delves into the intricate world of cytokines, vital signaling proteins that orchestrate the immune response and their pivotal role in modulating various immune functions. From their fundamental mechanisms to their therapeutic applications, this book offers a thorough examination of the latest trends and developments in leveraging cytokines for immunotherapy. The book includes chapters such as Cytokine-driven cancer immune evasion mechanisms, which explores how cytokines contribute to cancer cells' ability to evade the immune system. Cytokine-based immunotherapy in hematolymphoid malignancies is also explored, discussing the use of cytokines in treating blood cancers.

Targeting TNF-alpha examines the immunotherapeutic approach for alleviating neuropathic pain. The key role of immunomodulatory cytokines for the development of novel nk cell-based cancer therapies focuses on the importance of cytokines in developing new cancer treatments. Finally, complexities in the clinical development of TGF? inhibitors covers the challenges in creating inhibitors for TGF?.

Autoren/Hrsg.

Weitere Mitwirkende

Berraondo, Pedro

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Cytokine-driven cancer immune evasion mechanisms
Enrique Javier Arenas Lahuerta
2. Cytokine-based immunotherapy in hematolymphoid malignancies
Mário Sousa Pimenta Sr. and Nuno R. dos Santos
3. Targeting TNF-alpha: An immunotherapeutic approach for alleviating neuropathic pain
Mario García Domínguez
4. The key role of immunomodulatory cytokines for the development of novel nk cell-based cancer therapies
Maite Alvarez, Cristina Eguizabal, Anne Etxebarria, Diego Barriales and Andrea Saez de Cámara
5. Complexities in the clinical development of TGF? inhibitors
Javier Dotor
6. Dichotomy of IL-27 in tumor immunity
Fernando Aranda

Über Autor(innen)

Berraondo, Pedro
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.